Narcolepsy Treatment

Narcolepsy Treatment Comprehensive Study by Type (Sodium Oxybate, Antidepressants, Central Nervous System Stimulants, Others), Application (Primary Narcolepsy with Cataplexy, Primary Narcolepsy without Cataplexy, Narcolepsy Due to Medical Conditions, Unspecified Narcolepsy), Distribution Channel (Online, Offline), Drug Class (Vasopressors, CNS stimulants, Decongestants, Serotonin reuptake inhibitors), Narcolepsy (Type 1 (Sleepiness and cataplexy), Type 2) Players and Region - Global Market Outlook to 2030

Narcolepsy Treatment Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 34.8%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Narcolepsy Treatment Market Scope
Narcolepsy is a long-term neurological condition that causes fragmented sleep and excessive daytime sleepiness. Narcolepsy can range in severity from mild to severe. In severe cases, it can negatively impact social activities, school, work, and overall health and well-being. A person with narcolepsy may fall asleep at any time, such as while talking or driving. Symptoms tend to appear in a person’s teenage years or early 20s or 30s. In the United States, it is 50% more likely to affect females than males. Experts believe that around 1 in 2,000 people have narcolepsy. Narcolepsy is a sleep disorder that features excessive daytime sleepiness.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledTeva Pharmaceutical (Israel), Shire (United States), Jazz Pharmaceuticals (Ireland) and Arena Pharmaceuticals (United States)
CAGR34.8%


The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Narcolepsy Treatment market throughout the predicted period.

Teva Pharmaceutical (Israel), Shire (United States), Jazz Pharmaceuticals (Ireland) and Arena Pharmaceuticals (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Graymark Healthcare(United States) and Ligand Pharmaceuticals (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Narcolepsy Treatment market by Type , by Application (Primary Narcolepsy with Cataplexy, Primary Narcolepsy without Cataplexy, Narcolepsy Due to Medical Conditions and Unspecified Narcolepsy) and Region with country level break-up.

On the basis of geography, the market of Narcolepsy Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In March 2023, Teva Pharmaceutical Industries Ltd. announced that it has reached settlements with Sandoz, Actavis, Lupin and Apotex with respect to U.S. Patent 7,132,570 (the “570 patent”) for Teva’s wakefulness product, NUVIGIL® (armodafinil) tablets. These settlements dismiss a pending appeal with the United States Court of Appeals for the Federal Circuit of a trial court decision that found the ‘570 patent to be valid and infringed.
In June 2023, Avadel Pharmaceuticals plc announced that Lumryz—an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy—is now commercially available.


Influencing Trend:
Increase in the prevalence of narcolepsy

Market Growth Drivers:
Precision Medicine and Personalized Treatment Approaches

Challenges:
Stringent government regulation

Restraints:
lack of awareness

Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Narcolepsy Treatment Manufacturer, Government Regulatory and Research Organizations and End-Use Industry

Report Objectives / Segmentation Covered

By Type
  • Sodium Oxybate
  • Antidepressants
  • Central Nervous System Stimulants
  • Others
By Application
  • Primary Narcolepsy with Cataplexy
  • Primary Narcolepsy without Cataplexy
  • Narcolepsy Due to Medical Conditions
  • Unspecified Narcolepsy
By Distribution Channel
  • Online
  • Offline

By Drug Class
  • Vasopressors
  • CNS stimulants
  • Decongestants
  • Serotonin reuptake inhibitors

By Narcolepsy
  • Type 1 (Sleepiness and cataplexy)
  • Type 2

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Precision Medicine and Personalized Treatment Approaches
    • 3.3. Market Challenges
      • 3.3.1. Stringent government regulation
    • 3.4. Market Trends
      • 3.4.1. Increase in the prevalence of narcolepsy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Narcolepsy Treatment, by Type, Application, Distribution Channel, Drug Class, Narcolepsy and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Narcolepsy Treatment (Value)
      • 5.2.1. Global Narcolepsy Treatment by: Type (Value)
        • 5.2.1.1. Sodium Oxybate
        • 5.2.1.2. Antidepressants
        • 5.2.1.3. Central Nervous System Stimulants
        • 5.2.1.4. Others
      • 5.2.2. Global Narcolepsy Treatment by: Application (Value)
        • 5.2.2.1. Primary Narcolepsy with Cataplexy
        • 5.2.2.2. Primary Narcolepsy without Cataplexy
        • 5.2.2.3. Narcolepsy Due to Medical Conditions
        • 5.2.2.4. Unspecified Narcolepsy
      • 5.2.3. Global Narcolepsy Treatment by: Distribution Channel (Value)
        • 5.2.3.1. Online
        • 5.2.3.2. Offline
      • 5.2.4. Global Narcolepsy Treatment by: Drug Class (Value)
        • 5.2.4.1. Vasopressors
        • 5.2.4.2. CNS stimulants
        • 5.2.4.3. Decongestants
        • 5.2.4.4. Serotonin reuptake inhibitors
      • 5.2.5. Global Narcolepsy Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Narcolepsy Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Teva Pharmaceutical (Israel)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Shire (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Jazz Pharmaceuticals (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Arena Pharmaceuticals (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
  • 7. Global Narcolepsy Treatment Sale, by Type, Application, Distribution Channel, Drug Class, Narcolepsy and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Narcolepsy Treatment (Value)
      • 7.2.1. Global Narcolepsy Treatment by: Type (Value)
        • 7.2.1.1. Sodium Oxybate
        • 7.2.1.2. Antidepressants
        • 7.2.1.3. Central Nervous System Stimulants
        • 7.2.1.4. Others
      • 7.2.2. Global Narcolepsy Treatment by: Application (Value)
        • 7.2.2.1. Primary Narcolepsy with Cataplexy
        • 7.2.2.2. Primary Narcolepsy without Cataplexy
        • 7.2.2.3. Narcolepsy Due to Medical Conditions
        • 7.2.2.4. Unspecified Narcolepsy
      • 7.2.3. Global Narcolepsy Treatment by: Distribution Channel (Value)
        • 7.2.3.1. Online
        • 7.2.3.2. Offline
      • 7.2.4. Global Narcolepsy Treatment by: Drug Class (Value)
        • 7.2.4.1. Vasopressors
        • 7.2.4.2. CNS stimulants
        • 7.2.4.3. Decongestants
        • 7.2.4.4. Serotonin reuptake inhibitors
      • 7.2.5. Global Narcolepsy Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Narcolepsy Treatment: by Type(USD Million)
  • Table 2. Narcolepsy Treatment Sodium Oxybate , by Region USD Million (2018-2023)
  • Table 3. Narcolepsy Treatment Antidepressants , by Region USD Million (2018-2023)
  • Table 4. Narcolepsy Treatment Central Nervous System Stimulants , by Region USD Million (2018-2023)
  • Table 5. Narcolepsy Treatment Others , by Region USD Million (2018-2023)
  • Table 6. Narcolepsy Treatment: by Application(USD Million)
  • Table 7. Narcolepsy Treatment Primary Narcolepsy with Cataplexy , by Region USD Million (2018-2023)
  • Table 8. Narcolepsy Treatment Primary Narcolepsy without Cataplexy , by Region USD Million (2018-2023)
  • Table 9. Narcolepsy Treatment Narcolepsy Due to Medical Conditions , by Region USD Million (2018-2023)
  • Table 10. Narcolepsy Treatment Unspecified Narcolepsy , by Region USD Million (2018-2023)
  • Table 11. Narcolepsy Treatment: by Distribution Channel(USD Million)
  • Table 12. Narcolepsy Treatment Online , by Region USD Million (2018-2023)
  • Table 13. Narcolepsy Treatment Offline , by Region USD Million (2018-2023)
  • Table 14. Narcolepsy Treatment: by Drug Class(USD Million)
  • Table 15. Narcolepsy Treatment Vasopressors , by Region USD Million (2018-2023)
  • Table 16. Narcolepsy Treatment CNS stimulants , by Region USD Million (2018-2023)
  • Table 17. Narcolepsy Treatment Decongestants , by Region USD Million (2018-2023)
  • Table 18. Narcolepsy Treatment Serotonin reuptake inhibitors , by Region USD Million (2018-2023)
  • Table 19. South America Narcolepsy Treatment, by Country USD Million (2018-2023)
  • Table 20. South America Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 21. South America Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 22. South America Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 23. South America Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 24. South America Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 25. Brazil Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 26. Brazil Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 27. Brazil Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 28. Brazil Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 29. Brazil Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 30. Argentina Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 31. Argentina Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 32. Argentina Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 33. Argentina Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 34. Argentina Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 35. Rest of South America Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 36. Rest of South America Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 37. Rest of South America Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 38. Rest of South America Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 39. Rest of South America Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 40. Asia Pacific Narcolepsy Treatment, by Country USD Million (2018-2023)
  • Table 41. Asia Pacific Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 42. Asia Pacific Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 43. Asia Pacific Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 44. Asia Pacific Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 45. Asia Pacific Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 46. China Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 47. China Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 48. China Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 49. China Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 50. China Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 51. Japan Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 52. Japan Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 53. Japan Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 54. Japan Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 55. Japan Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 56. India Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 57. India Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 58. India Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 59. India Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 60. India Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 61. South Korea Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 62. South Korea Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 63. South Korea Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 64. South Korea Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 65. South Korea Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 66. Taiwan Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 67. Taiwan Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 68. Taiwan Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 69. Taiwan Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 70. Taiwan Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 71. Australia Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 72. Australia Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 73. Australia Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 74. Australia Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 75. Australia Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 76. Rest of Asia-Pacific Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 77. Rest of Asia-Pacific Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 78. Rest of Asia-Pacific Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 79. Rest of Asia-Pacific Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 80. Rest of Asia-Pacific Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 81. Europe Narcolepsy Treatment, by Country USD Million (2018-2023)
  • Table 82. Europe Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 83. Europe Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 84. Europe Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 85. Europe Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 86. Europe Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 87. Germany Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 88. Germany Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 89. Germany Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 90. Germany Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 91. Germany Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 92. France Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 93. France Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 94. France Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 95. France Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 96. France Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 97. Italy Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 98. Italy Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 99. Italy Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 100. Italy Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 101. Italy Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 102. United Kingdom Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 103. United Kingdom Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 104. United Kingdom Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 105. United Kingdom Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 106. United Kingdom Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 107. Netherlands Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 108. Netherlands Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 109. Netherlands Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 110. Netherlands Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 111. Netherlands Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 112. Rest of Europe Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 113. Rest of Europe Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 114. Rest of Europe Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 115. Rest of Europe Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 116. Rest of Europe Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 117. MEA Narcolepsy Treatment, by Country USD Million (2018-2023)
  • Table 118. MEA Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 119. MEA Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 120. MEA Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 121. MEA Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 122. MEA Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 123. Middle East Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 124. Middle East Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 125. Middle East Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 126. Middle East Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 127. Middle East Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 128. Africa Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 129. Africa Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 130. Africa Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 131. Africa Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 132. Africa Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 133. North America Narcolepsy Treatment, by Country USD Million (2018-2023)
  • Table 134. North America Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 135. North America Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 136. North America Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 137. North America Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 138. North America Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 139. United States Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 140. United States Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 141. United States Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 142. United States Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 143. United States Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 144. Canada Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 145. Canada Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 146. Canada Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 147. Canada Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 148. Canada Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 149. Mexico Narcolepsy Treatment, by Type USD Million (2018-2023)
  • Table 150. Mexico Narcolepsy Treatment, by Application USD Million (2018-2023)
  • Table 151. Mexico Narcolepsy Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 152. Mexico Narcolepsy Treatment, by Drug Class USD Million (2018-2023)
  • Table 153. Mexico Narcolepsy Treatment, by Narcolepsy USD Million (2018-2023)
  • Table 154. Company Basic Information, Sales Area and Its Competitors
  • Table 155. Company Basic Information, Sales Area and Its Competitors
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Narcolepsy Treatment: by Type(USD Million)
  • Table 159. Narcolepsy Treatment Sodium Oxybate , by Region USD Million (2025-2030)
  • Table 160. Narcolepsy Treatment Antidepressants , by Region USD Million (2025-2030)
  • Table 161. Narcolepsy Treatment Central Nervous System Stimulants , by Region USD Million (2025-2030)
  • Table 162. Narcolepsy Treatment Others , by Region USD Million (2025-2030)
  • Table 163. Narcolepsy Treatment: by Application(USD Million)
  • Table 164. Narcolepsy Treatment Primary Narcolepsy with Cataplexy , by Region USD Million (2025-2030)
  • Table 165. Narcolepsy Treatment Primary Narcolepsy without Cataplexy , by Region USD Million (2025-2030)
  • Table 166. Narcolepsy Treatment Narcolepsy Due to Medical Conditions , by Region USD Million (2025-2030)
  • Table 167. Narcolepsy Treatment Unspecified Narcolepsy , by Region USD Million (2025-2030)
  • Table 168. Narcolepsy Treatment: by Distribution Channel(USD Million)
  • Table 169. Narcolepsy Treatment Online , by Region USD Million (2025-2030)
  • Table 170. Narcolepsy Treatment Offline , by Region USD Million (2025-2030)
  • Table 171. Narcolepsy Treatment: by Drug Class(USD Million)
  • Table 172. Narcolepsy Treatment Vasopressors , by Region USD Million (2025-2030)
  • Table 173. Narcolepsy Treatment CNS stimulants , by Region USD Million (2025-2030)
  • Table 174. Narcolepsy Treatment Decongestants , by Region USD Million (2025-2030)
  • Table 175. Narcolepsy Treatment Serotonin reuptake inhibitors , by Region USD Million (2025-2030)
  • Table 176. South America Narcolepsy Treatment, by Country USD Million (2025-2030)
  • Table 177. South America Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 178. South America Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 179. South America Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 180. South America Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 181. South America Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 182. Brazil Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 183. Brazil Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 184. Brazil Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 185. Brazil Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 186. Brazil Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 187. Argentina Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 188. Argentina Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 189. Argentina Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 190. Argentina Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 191. Argentina Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 192. Rest of South America Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 193. Rest of South America Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 194. Rest of South America Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 195. Rest of South America Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 196. Rest of South America Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 197. Asia Pacific Narcolepsy Treatment, by Country USD Million (2025-2030)
  • Table 198. Asia Pacific Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 199. Asia Pacific Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 200. Asia Pacific Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 201. Asia Pacific Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 202. Asia Pacific Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 203. China Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 204. China Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 205. China Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 206. China Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 207. China Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 208. Japan Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 209. Japan Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 210. Japan Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 211. Japan Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 212. Japan Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 213. India Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 214. India Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 215. India Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 216. India Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 217. India Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 218. South Korea Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 219. South Korea Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 220. South Korea Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 221. South Korea Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 222. South Korea Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 223. Taiwan Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 224. Taiwan Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 225. Taiwan Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 226. Taiwan Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 227. Taiwan Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 228. Australia Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 229. Australia Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 230. Australia Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 231. Australia Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 232. Australia Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 233. Rest of Asia-Pacific Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 234. Rest of Asia-Pacific Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 235. Rest of Asia-Pacific Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 236. Rest of Asia-Pacific Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 237. Rest of Asia-Pacific Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 238. Europe Narcolepsy Treatment, by Country USD Million (2025-2030)
  • Table 239. Europe Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 240. Europe Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 241. Europe Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 242. Europe Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 243. Europe Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 244. Germany Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 245. Germany Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 246. Germany Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 247. Germany Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 248. Germany Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 249. France Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 250. France Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 251. France Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 252. France Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 253. France Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 254. Italy Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 255. Italy Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 256. Italy Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 257. Italy Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 258. Italy Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 259. United Kingdom Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 260. United Kingdom Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 261. United Kingdom Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 262. United Kingdom Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 263. United Kingdom Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 264. Netherlands Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 265. Netherlands Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 266. Netherlands Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 267. Netherlands Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 268. Netherlands Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 269. Rest of Europe Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 270. Rest of Europe Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 271. Rest of Europe Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 272. Rest of Europe Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 273. Rest of Europe Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 274. MEA Narcolepsy Treatment, by Country USD Million (2025-2030)
  • Table 275. MEA Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 276. MEA Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 277. MEA Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 278. MEA Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 279. MEA Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 280. Middle East Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 281. Middle East Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 282. Middle East Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 283. Middle East Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 284. Middle East Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 285. Africa Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 286. Africa Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 287. Africa Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 288. Africa Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 289. Africa Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 290. North America Narcolepsy Treatment, by Country USD Million (2025-2030)
  • Table 291. North America Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 292. North America Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 293. North America Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 294. North America Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 295. North America Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 296. United States Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 297. United States Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 298. United States Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 299. United States Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 300. United States Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 301. Canada Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 302. Canada Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 303. Canada Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 304. Canada Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 305. Canada Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 306. Mexico Narcolepsy Treatment, by Type USD Million (2025-2030)
  • Table 307. Mexico Narcolepsy Treatment, by Application USD Million (2025-2030)
  • Table 308. Mexico Narcolepsy Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 309. Mexico Narcolepsy Treatment, by Drug Class USD Million (2025-2030)
  • Table 310. Mexico Narcolepsy Treatment, by Narcolepsy USD Million (2025-2030)
  • Table 311. Research Programs/Design for This Report
  • Table 312. Key Data Information from Secondary Sources
  • Table 313. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Narcolepsy Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Narcolepsy Treatment: by Application USD Million (2018-2023)
  • Figure 6. Global Narcolepsy Treatment: by Distribution Channel USD Million (2018-2023)
  • Figure 7. Global Narcolepsy Treatment: by Drug Class USD Million (2018-2023)
  • Figure 8. South America Narcolepsy Treatment Share (%), by Country
  • Figure 9. Asia Pacific Narcolepsy Treatment Share (%), by Country
  • Figure 10. Europe Narcolepsy Treatment Share (%), by Country
  • Figure 11. MEA Narcolepsy Treatment Share (%), by Country
  • Figure 12. North America Narcolepsy Treatment Share (%), by Country
  • Figure 13. Global Narcolepsy Treatment share by Players 2023 (%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Teva Pharmaceutical (Israel) Revenue, Net Income and Gross profit
  • Figure 16. Teva Pharmaceutical (Israel) Revenue: by Geography 2023
  • Figure 17. Shire (United States) Revenue, Net Income and Gross profit
  • Figure 18. Shire (United States) Revenue: by Geography 2023
  • Figure 19. Jazz Pharmaceuticals (Ireland) Revenue, Net Income and Gross profit
  • Figure 20. Jazz Pharmaceuticals (Ireland) Revenue: by Geography 2023
  • Figure 21. Arena Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 22. Arena Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 23. Global Narcolepsy Treatment: by Type USD Million (2025-2030)
  • Figure 24. Global Narcolepsy Treatment: by Application USD Million (2025-2030)
  • Figure 25. Global Narcolepsy Treatment: by Distribution Channel USD Million (2025-2030)
  • Figure 26. Global Narcolepsy Treatment: by Drug Class USD Million (2025-2030)
  • Figure 27. South America Narcolepsy Treatment Share (%), by Country
  • Figure 28. Asia Pacific Narcolepsy Treatment Share (%), by Country
  • Figure 29. Europe Narcolepsy Treatment Share (%), by Country
  • Figure 30. MEA Narcolepsy Treatment Share (%), by Country
  • Figure 31. North America Narcolepsy Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Teva Pharmaceutical (Israel)
  • Shire (United States)
  • Jazz Pharmaceuticals (Ireland)
  • Arena Pharmaceuticals (United States)
Additional players considered in the study are as follows:
Graymark Healthcare(United States) , Ligand Pharmaceuticals (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 246 Pages 59 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Narcolepsy Treatment Quantitative research analysis
Narcolepsy Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Narcolepsy Treatment Market are by type [Sodium Oxybate, Antidepressants, Central Nervous System Stimulants and Others], by end use application [Primary Narcolepsy with Cataplexy, Primary Narcolepsy without Cataplexy, Narcolepsy Due to Medical Conditions and Unspecified Narcolepsy].
The Narcolepsy Treatment Market is gaining popularity and expected to see strong valuation by 2030.
  • Precision Medicine and Personalized Treatment Approaches

Know More About Narcolepsy Treatment Report?

Have a Query? Click Here

Other Related Reports

Biosimilar Drug Comprehensive Study by Type (Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone, Insulin, Others}, Recombinant Glycosylated Proteins {Erythropoietin, Monoclonal A...
$ 3750
Sinusitis Drugs Comprehensive Study by Type (Analgesics, Antibiotics, Antihistamines, Corticosteroids, Decongestants, Sulphonamides), Application (Acute Sinusitis, Chronic Sinusitis), Treatment (Anti...
$ 3650
Barbiturate Drugs Comprehensive Study by Type (Phenobarbital, Amobarbital, Secobarbital, Pentobarbital, Others), Application (Insomnia, Seizures, Headaches, Others), Nature (Ultra-Short Acting Barbit...
$ 3750
Pigmented Villonodular Synovitis Drug Comprehensive Study by Type (Cabiralizumab, Emactuzumab, Mcs-110, Nilotinib, Others), Application (Reduces Swelling, Relieves Pain, Others), Distribution Channel...
$ 3650
Immunotherapy Drugs Comprehensive Study by Type (Monoclonal Antibodies, Adult Vaccines (Preventive Vaccines, Therapeutic Vaccines), Checkpoint Inhibitors, Interferons Alpha & Beta, Interleukins, Othe...
$ 3750
Allyl Methacrylate Comprehensive Study by Type (Allyl Methacrylate 98%, Allyl Methacrylate 99.5%), Application (Paints& Coatings, Floor Polishes, Dentistry Materials, Other), Distribution Channel (Di...
$ 3350